Setting 
My Cart

Ordered before 17:30, shipped today - Support: (012) 800 456 789

Track Your Order

Toggle Nav
mobile icon
Close
  • Menu
  • Setting

Signaling Pathways

Items 21-30 of 51

Page
per page
  1. Gefitinib hydrochloride
    A3433 Gefitinib hydrochloride
    Target: EGFR
    Summary: Potent EGFR inhibitor
      insoluble in EtOH; ≥4.28 mg/mL
  2. LDE225 Diphosphate
    A3543 LDE225 Diphosphate
    Target: Smoothened
    Summary: Smo antagonist
      ≥27.85 mg/mL
  3. LY2090314
    A3570 LY2090314
    Target: GSK-3
    Summary: Potent GSK-3 inhibitor
      insoluble in H2O; ≥91 mg/mL
  4. LY2801653
    A3573 LY2801653
    Target: MET
    Summary: MET inhibitor
      ≥27.65 mg/mL
  5. Motesanib
    A3632 Motesanib
    Target: VEGFR
    Summary: Inhibitor of Flk-1/Flt-4/PDGFR-/c-Kit
      ≥42 mg/mL
  6. FRAX597
    B1162 FRAX597
     1 Citation
    Target: PAK
    Summary: PAK inhibitor,potent and ATP-competitive
      ≥27.9 mg/mL
  7. LDE225 (NVP-LDE225,Erismodegib)
    B2266 LDE225 (NVP-LDE225,Erismodegib)
     1 Citation
    Target: Smoothened
    Summary: Smoothened inhibitor,potent and selective
      ≥24.3 mg/mL
  8. LY2606368
    B1088 LY2606368
    Target: Chk
    Summary: CHK1 inhibitor
      insoluble in DMSO
  9. Tranexamic Acid
    B1858 Tranexamic Acid
    Target: fibrinolysis
    Summary: competitive inhibitor of plasminogen activation
      insoluble in EtOH; insoluble in DMSO; ≥6.6 mg/mL
  10. AS-252424
    B2180 AS-252424
    Target: Akt|PI3K
    Summary: PI3Kγ inhibitor,novel and potent
      insoluble in EtOH; insoluble in H2O; ≥30.5 mg/mL

Items 21-30 of 51

Page
per page